NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery systems, today announced the appointment of
Arie Mayer, Ph.D. to its Board of
Directors.
Dr. Arie Mayer is currently the
Managing Director and Chairman of the Board of Merck Life Science
Israel (formerly Sigma-Aldrich Israel Ltd.,) and has held that
position since January 2010.
Dr. Mayer has held various roles with Sigma-Aldrich Israel
Ltd. since 1995 and was instrumental in introducing and developing
the Cell Culture and Molecular Biology business for Sigma Aldrich
Israel. Dr. Mayer holds a Bachelor of Science in chemistry
from Hebrew University and a Ph.D. in
biochemistry from Israel Institute of Technology. In
addition, he has publications as a main author in the following
journals: Science, Journal of Biological Chemistry,
New Scientist and the Journal of Cell Sciences.
"We are excited to welcome Dr. Mayer to our Board of Directors.
He brings deep and valuable experience in scale up manufacturing as
well as solid commercial expertise to the Company. His
guidance and leadership in these areas will be critical as we
pursue late-stage development of our POD Technology," said
Nadav Kidron, CEO of Oramed.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in
the field of oral delivery solutions for drugs currently delivered
via injection. Established in 2006, with offices in New
York and Israel, Oramed has developed a novel Protein
Oral Delivery (POD™) technology that is based on more
than 30 years of research by scientists
at Jerusalem's Hadassah Medical Center. Oramed is seeking
to revolutionize the treatment of diabetes through its proprietary
lead candidate, ORMD-0801, which has the potential to be the
first commercial oral insulin capsule for the treatment
of Type 2 and Type 1 diabetes. The Company has completed
multiple Phase II clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration. In
addition, Oramed is developing an oral GLP-1 (Glucagon-like
peptide-1) analog capsule, ORMD-0901.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the potential of
ORMD-0801 to be the first commercial oral insulin capsule for the
treatment of diabetes or revolutionizing the treatment of diabetes
with our products. In addition, historic results of scientific
research and clinical trials do not guarantee that the conclusions
of future research or trials will suggest identical or even similar
conclusions. These forward-looking statements are based on the
current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties
related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and
Exchange Commission.
Company Contact
Estee
Yaari
+1-844-9-ORAMED
Email: estee@oramed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oramed-appoints-dr-arie-mayer-to-board-of-directors-300970023.html
SOURCE Oramed Pharmaceuticals Inc.